Multi-endpoint biological monitoring in combined, carcinogenic occupational exposures.

We aimed to develop a relevant multi-endpoint biomonitoring system by studying different genotoxicity biomarkers in complex carcinogenic exposures under occupational situations. Altogether 109 workers were followed in five different workplaces. The combined carcinogenic exposures were monitored in the urine and peripheral blood samples using Ames mutagenicity test and cytogenetic analyzes. The different genotoxicity endpoints studied showed different results in the same carcinogenic exposure situations. The urinary mutagenicity tests provided more information and proved to be more sensitive compared to the cytogenetic tests in the majority of cases. In complex exposures multistep biomonitoring panel should be applied, because the exact mechanisms of the combination of single exposing agents are not known. Such a panel should involve monitoring different endpoints, e.g. point mutations, chromosomal mutations. A relatively affordable and rapid testing panel was developed using validated tests as Ames and cytogenetic assays, but its practical use should be confirmed by further investigations.

Automation of the in vitro micronucleus and chromosome aberration assay for the assessment of the genotoxicity of the particulate and gas-vapor phase of cigarette smoke.

Total particulate matter (TPM) and the gas-vapor phase (GVP) of mainstream smoke from the Reference Cigarette 3R4F were assayed in the cytokinesis-block in vitro micronucleus (MN) assay and the in vitro chromosome aberration (CA) assay, both using V79-4 Chinese hamster lung fibroblasts exposed for up to 24 h. The Metafer image analysis platform was adapted resulting in a fully automated evaluation system of the MN assay for the detection, identification and reporting of cells with micronuclei together with the determination of the cytokinesis-block proliferation index (CBPI) to quantify the treatment-related cytotoxicity. In the CA assay, the same platform was used to identify, map and retrieve metaphases for a subsequent CA evaluation by a trained evaluator. In both the assays, TPM and GVP provoked a significant genotoxic effect: up to 6-fold more micronucleated target cells than in the negative control and up to 10-fold increases in aberrant metaphases. Data variability was lower in the automated version of the MN assay than in the non-automated. It can be estimated that two test substances that differ in their genotoxicity by approximately 30% can statistically be distinguished in the automated MN and CA assays. Time savings, based on man hours, due to the automation were approximately 70% in the MN and 25% in the CA assays. The turn-around time of the evaluation phase could be shortened by 35 and 50%, respectively. Although only cigarette smoke-derived test material has been applied, the technical improvements should be of value for other test substances.

Optimizing screening and mating strategies for phenotype-driven recessive N-ethyl-N-nitrosourea screens in mice.

Phenotype-driven N-ethyl-N-nitrosourea (ENU) mutagenesis screens in the mouse are being used to elucidate gene function and develop disease models. Many of the earlier screens focused on identifying dominant mutations, whereas many newer mutagenesis programs have arisen that focus on identifying recessive mutations. Recessive screens require more complex breeding and phenotyping procedures, yet little information is available on the optimal breeding and phenotyping strategies for identifying recessive mutations. Optimization involves minimizing the numbers of mice that must be bred and subjected to phenotypic screens while maximizing the number of mutant phenotypes that can be identified. Analysis of expected frequencies of mutants has been used to determine which of the typically used mating and screening strategies will produce the best returns in terms of identifying recessive phenotypes. As a general guideline, to minimize the number of mice to be screened, the optimal strategy is to mate a single generation 2 (G2) female and G1 male and screen either 11 or 17 G3 offspring to obtain at least 1 or 2 homozygous mutants, respectively. When the expense of producing and housing the mice is the greatest cost factor and the phenotype is so robust that a single outlier will suffice, then the optimal strategy is to mate 2 G2 sisters with the G1 male parent and screen a single litter from each. Intercrossing of G2 brothers and sisters is not an efficient method for maximizing returns from ENU screens.

The fast halo assay: an improved method to quantify genomic DNA strand breakage at the single-cell level.

The present study describes the improvement of a technique, the alkaline-halo assay (AHA), for the assessment of DNA single-strand breakage at the single-cell level. AHA involves a series of sequential steps in which cells are embedded in melted agarose and spread onto microscope slides, incubated in a high-salt alkaline lysis solution, then in a hypotonic alkaline solution and, finally, stained with ethidium bromide (EB). Under these conditions, single-stranded DNA fragments diffuse radially from the nuclear cage and generate a fluorescent image that resembles a halo concentric to the nuclear remnants: the area of the halo is a direct function of the extent of DNA strand scission. These phenomena can be conveniently monitored with a fluorescence microscope and quantified by image-processing analysis. The behaviour of single-stranded DNA fragments under the conditions of the modified assay, called fast halo assay (FHA), is essentially the same as in AHA. The modifications consist in the simplification of the lysis, denaturation and staining procedures, and allow, as compared with AHA, the preparation of samples within 15 min, with a two-third reduction in total processing time, using only two reagents to promote DNA extraction and staining: NaOH and EB. A variation of the FHA operating at non-denaturing conditions to discriminate apoptotic cells from non-apoptotic cells bearing DNA single-strand breaks is also illustrated. To benchmark FHA sensitivity and reliability, the DNA single-strand breaks (SSBs) resulting either from exposure of cultured mammalian cells to different DNA-damaging agents or from secondary apoptotic DNA cleavage, have been quantified and results compared with the outcomes of reference techniques run in parallel, namely AHA, comet assay and Hoechst 33342 staining. The results indicate that FHA has the same reliability and sensitivity of the reference assays, but presents the additional advantages of being inexpensive, more rapid and strikingly simple.

Assessment of the mutagenic potency of sewage sludges contaminated with polycyclic aromatic hydrocarbons by an Ames sludges for fluctuation assay.

The mutagenicity of crude extracts and subfractions of two samples of a reference sewage sludge material and two sewage sludges from two wastewater treatment plants (WWTP), one urban and the other one urban mixed with industrial, was assessed using an Ames fluctuation assay based on 384-well microtiter plates with liquid cultures. Crude extracts of sludges were obtained by ultrasonic extraction with dichloromethane/methanol, and further column fractionation yielded two fractions, one of which containing mutagenic polycyclic aromatic hydrocarbons (PAHs). Quantitative analysis performed by gas chromatography-mass spectrometry gave sum concentrations of the 16 PAHs listed as priority pollutants by the U.S. Environmental Protection Agency at levels between 1,305 and 2,442 microg/kg. Subjecting crude extracts and column fractions to the mutagenicity assay with Salmonella strains TA98 and TA 100 provided good qualitative correlation between the presence of mutagenic PAH and the induction of gene mutations. In general, the crude extracts and the PAH-fractions induced positive responses in the assay with both bacterial strains on metabolic activation by S9 rat-liver homogenate, whereas direct-acting mutagens were not detectable. In the assay with the real sludge samples of two different WWTPs, TA98 proved to be more sensitive than TA100; however, similar sensitivities of the tester strains were observed for two reference sewage sludge materials of the same origin. The outcomes of the Ames fluctuation assay demonstrated its performance as a cost-effective and relatively rapid screening tool to assess the genotoxic potential of complex environmental samples.

Rater agreement and utility of the mutagen-induced chromosome damage assay.

Chromosomal damage in peripheral blood lymphocytes induced by short-term in vitro exposure to the cytotoxic antibiotic bleomycin was first described in 1983 and proposed as a phenotypic assay for chromosome instability. This assay was subsequently described as potentially useful in assessing an individual's risk to environmental carcinogens in 1989. Since 1995 numerous published studies have used this assay to assess risk for cancer in the aerodigestive tract, particularly lung cancer, in various ethnic populations. Odds ratios up to 8.5 have been reported for individuals deemed "mutagen sensitive" (defined as > or = 1 chromatid break per metaphase averaged in 50 metaphases analyzed). While this phenotypic assay is appealing for lung cancer risk assessment it has not been reproduced by other investigators. Because of our interest in lung cancer biology, epidemiology, and genetics, we sought to independently assess the rater agreement of this assay. We found that 1) the assay is laborious to conduct (8 hours of labor) and relatively expensive (> $100), yet reducing the number of metaphases from 50 to 20 produced a reliable, less expensive, and less laborious test; and 2) the rater agreement of individual metaphase readings is poor, but agreement for a summary measure is high.

Principles and practices of integrating genotoxicity evaluation into routine toxicology studies: a pharmaceutical industry perspective.

In this article, an integrated in vivo genotoxicity testing philosophy and a practical approach, as applied to pharmaceuticals, are described. Recently, there has been an effort to integrate the rodent (primarily rat) micronucleus assay with routine 2-4-week toxicokinetic studies. This approach has several advantages: 1) it utilizes the general principles of toxicology that govern the overall toxicity profile of a test substance; 2) factors such as the dose and/or route of drug administration, drug metabolism, principles of toxicokinetics, and saturation of defense mechanisms are considered in evaluating genotoxicity; 3) it uses the concept of administering multiple tolerable doses aiding in achieving steady state plasma drug levels, which is more relevant for risk assessment compared to high acute doses; and 4) it helps minimize the amount of drug, number of animals used, and other resources. This integration approach can be extended to other toxicology studies and other relevant genotoxicity endpoints may be assessed. Based on the experience in our laboratory, integrating micronucleus assessment in routine toxicology testing is promising and should be utilized when practical.

Special considerations for conducting genotoxicity tests with protein materials.

Standard genotoxicity tests are often inappropriate for testing new biological entities, in particular for recombinant proteins which are nature-identical. Arguments that these may contain mutagenic impurities are not substantiated; however, we have produced evidence that such impurities would be detected amidst a vast excess of protein. Concerns that human patients receiving therapy may be at risk from higher-than-physiological levels of proteins are also somewhat theoretical. However, it is apparent that genotoxicity testing will be required for these products for the time being, even if pragmatic approaches reduce the battery of in vitro tests to Ames and chromosomal aberrations only, and reduce the top dose in vivo to 1000x the human therapeutic dose. There is a number of physical and chemical properties of proteins that demand special approaches to methodology if the tests are to produce accurate results. The potential for adsorption to certain forms of glass and plastic means special care must be taken in dissolving and diluting test solutions; adherence to filters means special low protein binding, non-pyrogenic filters should be used for sterilisation of test solutions, where this is necessary; freeze-dried powders aliquotted in multiple vials should be dissolved in minimal solvent and cascaded from vial to vial rather than trying to empty the solid contents for bulk weighing. As proteins are often supplied in solution, in order to achieve sufficiently high test concentrations, it may be necessary to resuspend test bacteria/cells in the test solutions for short periods of time before centrifuging and resuspending in selective or growth media.(ABSTRACT TRUNCATED AT 250 WORDS)

A modified SOS-Chromotest procedure to test for genotoxicity and cytotoxicity in sediments directly without extraction.

A modified SOS-Chromotest bioassay using a chromogenic pad (pad procedure) was developed to test for genotoxicity in sediments directly without extraction. This test is based on the de novo synthesis of beta-galactosidase enzyme by a genetically-engineered E. coli strain PQ37. In the bioassay, an exponential growth phase antibiotic-containing culture of the test bacterium is introduced into a series of tubes with the first tube containing 0.1 gram of sediment. Serial dilutions are then made and the tubes of sediment plus bacterial culture are incubated at 37 degrees C for four hours, followed by placing a drop of each mixture on a chromogenic pad and additional incubation for 20 hours at 37 degrees C. The solid particulates are then washed off with tap water and positive (genotoxic) activity is noted by the presence of a distinctive blue colour on the pad. The SOS-Chromotest pad procedure may be best used as a relative measure of genotoxicity by comparing results to a reference sample. In addition it can also determine sediment cytotoxicity by comparing samples spiked with a genotoxic standard (i.e., 4-nitroquinoline-N-oxide). Preliminary results suggest that this new bioassay is highly sensitive, consistent and discriminating.

Statistical design and analysis of mutation studies in transgenic mice.

We have been working on identifying sources of variability in data from transgenic mouse mutation assays in order to develop appropriate statistical methods and designs for routine studies. Data from our lab and elsewhere point to the presence of significant animal-to-animal variability, which must be taken into account in statistical hypothesis tests. Here, the usual Cochran-Armitage (CA) test for trend in mutant frequencies, which takes the transgene as the experimental unit, and a generalized Cochran-Armitage test (GCA), which takes the animal as the experimental unit, are contrasted in computer simulations that help to quantify the differences between these statistical tests. The simulations report the statistical power of each test to detect treatment group differences, and their type I error rates. We find in general that the GCA test performs poorly compared to the CA test when it is appropriate to take the transgene as the experimental unit, and the study also uses a small number of animals. However, the CA test performs poorly in small group-size studies when the animal is the appropriate experimental unit. Extensions of the computer simulations allow for identification of cost-effective experimental designs. The results emphasize that the benefits of using additional animals in these mutation studies can be realized without substantial increases in costs. Here we illustrate the methods for liver studies in our lab. These methods can be used to derive optimal experimental designs for any combination of spontaneous mutant frequency and animal-to-animal variability.

Initial experiences and future directions for transgenic mouse mutation assays.

Transgenic mice have introduced new possibilities in the field of mutation research and safety testing. Using lacZ transgenic mice (Muta Mouse), we have combined the peripheral blood micronucleus assay with the transgenic mouse mutation assay, enabling the concomitant detection of gene mutations and micronucleus induction in vivo in the same animals (Suzuki et al., 1993). Several mutagens, i.e., mitomycin C (MMC), ethyl nitrosourea (ENU), ethyl methanesulfonate (EMS) and diethyl nitrosamine (DEN), were tested in this combined assay. All of them increased the lacZ mutant frequency in bone marrow or liver, and all except DEN induced micronuclei in peripheral blood. These initial studies demonstrated that genotoxicity in vivo could be detected with these two endpoints and, more importantly, that some specificity exists among these tissues analyzed. Although transgenic mouse mutation assays have many potential applications in in vivo mutation research, several problems stand in the way of wider use. Paramount among these are cost and labor intensiveness. The color screening systems for lacZ or lacI mutation detection require large numbers of plates and tedious scoring processes. In order to make significant advances in this field, it will be necessary to use positive selection for induced mutants, such as has been described recently for the lacZ and lacI transgenic mouse models.

A consideration of the advantages and potential difficulties of the use of transgenic mice for the study of germinal mutations.

The utility of transgenic mouse systems in the study of germ-cell mutations is discussed. These systems promise to fill a gap in the evaluation of potential genotoxic agents between the identification of mutagens in short-term test systems and evaluation of human genetic risk. A less appreciated major contribution that transgenic systems can make is as research tools for achieving an understanding of the mechanisms of mutation induction in germ cells. Questions concerning the germ-cell mutations using transgenic systems include whether these systems can detect large genetic lesions, whether they can detect mutations in repair-deficient male germ-cell stages, whether it is valid to extrapolate mutational spectra from transgenes to endogenous genes, and whether the transgenic systems can be used to address issues concerning differences in locus sensitivities to mutation. Available shuttle-vector systems are not suitable for the direct detection of mutations in female germ cells. Future directions for development include the use of the present systems in research and testing and the development of systems with new capabilities.

How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans?: lesions from the human factor IX gene.

Transgenic mutation-detection systems have been pioneered in mice, but the approach is applicable to any species in which transgenic animals can be generated. The observed mutations seen in mutation-detection systems are influenced by the underlying pattern of mutation, i.e., the mutational pattern that occurs in wild-type organisms in endogenous segments of DNA that are not under selective pressure. Unfortunately, the biology of most genes and assays markedly skew the underlying pattern of mutation. Herein, we raise multiple issues that must be addressed in order to estimate the underlying pattern of spontaneous mutation from transgenic mouse mutation-detection systems. If these issues can be addressed, the underlying pattern of spontaneous mutation can then be deduced for multiple cell types and for transgenes integrated into different parts of the genome. Even though transgenic methodology cannot be applied directly to humans, it is likely that comparable data on the underlying pattern of spontaneous mutation will be available in humans. Such data are currently available for germline mutations in the factor IX gene. These data are reviewed because of their relevance to two of the multiple issues that must be addressed in transgenic mouse mutation-detection systems: (1) How can the underlying pattern of mutation be deduced from the observed pattern? and (2) How similar are the underlying patterns of mutation in humans and in mice? The analysis of recent germ-line mutation in the factor IX gene yield estimates of the mutation rates per base pair per generation. In brief, the mutation rates vary from 0.037 x 10(-10) for deletions (> 20 bp) to 360 x 10(-10) for transitions at the dinucleotide CpG. If these mutation rates are extrapolated to the entire genome, the aggregate mutation rate is estimated to be 36 x 10(-10). This implies that the diploid genome of each person contains about 21 de novo mutations. In the future, the underlying pattern of spontaneous mutation will be deduced for multiple human genes and these will serve as benchmarks to assess the similarity of the mutational process in humans and in mice.

A recombination-based transgenic mouse system for genotoxicity testing.

It is well established that mutagens induce recombination in cultured cells and experimental organisms. Presumably, this is a consequence of the DNA-damage-triggering cellular-repair mechanisms. The relationship between recombination and mutagenicity has been exploited in submammalian organisms, such as yeast, to assay the ability of chemical agents and radiation to induce a form of recombination called gene conversion--the non-reciprocal transfer of genetic information. This work has demonstrated the efficacy of predicting mutagenicity on the basis of recombination induction. Here, we describe the utilization of a transgenic mouse system for efficient detection of germ-line gene-conversion events as a mutagen-screening tool. These mice contain two mutually defective reporter (lacZ) genes under the regulatory control of a spermatogenesis-specific promoter. A particular intrachromosomal gene conversion event must occur for the generation of functional lacZ activity. Conversion events are visualized by histochemical staining or flow cytometric analysis of transgenic spermatids. The highly mutagenic compound chlorambucil induced a several fold percentage-wise increase of lacZ-positive spermatids, whereas acrylamide, a weak genotoxin, produced no marked increase in converted spermatids. The results indicate that recombination-based transgenic mouse models for genotoxin screening present a viable option for inexpensive and rapid whole-animal mutagen testing. The particular mice we describe may ultimately prove to be a useful tool for identifying agents which can cause heritable genetic mutations in humans.

Scientific and cost-effectiveness criteria in selecting batteries of short-term tests.

The scientific and cost-effectiveness criteria introduced in this paper can be applied to published datasets and current and proposed batteries of short-term tests. The reports in the current volume will provide a wealth of additional material for such evaluations, but more systematically obtained information will be necessary to assess both the internal and external validity of these tests. Individual tests and batteries of tests should be standardized, employ positive controls, generate results capable of quantitative analyses that may make dichotomous classification as "positive" and "negative" obsolete, be interpreted in light of mechanisms of action, and be cost-effective on a grand scale. For regulatory purposes our long-term goal should be to replace the whole animal lifetime bioassay with an appropriate and cost-effective set of short-term tests.

Cost-effectiveness of short-term tests for carcinogenicity.

Most chemicals to which we are exposed are not properly tested for carcinogenicity. The latest methods of in vitro testing provide a way of screening with sufficient accuracy to remedy this situation.

Strategies to reduce the cost of mutagenicity screening with the Salmonella assay.

An extensive Salmonella assay database was analyzed in order to develop strategies to reduce costs of screening chemicals for mutagenicity. This database was obtained from testing 941 samples (representing 799 chemicals), 36% of which were judged mutagenic. Strains TA98, TA100, TA1535, and TA1537 without activation, with rat liver S-9, and with hamster liver S-9, make up the 12 strain/activation combinations considered here. The testing strategies examined consist of two or three stages; a positive result at any stage is regarded as definitive and stops the testing. Sequential testing improves efficiency by eliminating the need for further experimentation once a chemical has been found to be mutagenic. Consequently, costs and effort are reduced. For screening chemicals in the Salmonella assay, it is our recommendation that a sequential testing scheme be adopted whose initial stage consists of TA100.